anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention comprises analogs of the CA 1  A 2  X motif of the protein Ras that is modified by farnesylation in vivo. These CA 1  A 2  X analogs inhibit the farnesyl-protein transferase and the farnesylation of certain proteins. Furthermore, these CA 1  A 2  X analogs differ from those previously described as inhibitors of farnesyl-protein transferase in that they do not have a thiol moiety. The lack of the thiol offers unique advantages in terms of improved pharmacokinetic behavior in animals, prevention of thiol-dependent chemical reactions, such as rapid autoxidation and disulfide formation with endogenous thiols, and reduced systemic toxicity. The compounds of the instant invention also incorporate a cyclic amine moiety in the A 2  position of the motif. Further contained in this invention are chemotherapeutic compositions containing these farnesyl transferase inhibitors and methods for their production.
When craniotomy surgery was done, inhalation anesthestic sevoflurane level will control at 2.63%-2.97%, we perform suction secretions in endotracheal tube and oral cavity, then switching endotracheal tube to laryngeal mask. Then we discontinue inhalation anesthestic sevoflurane and support oxygen at the rate of 6L/min. At the same time, give neostigmine 0.05-0.07 mg/kg and glycopyrrolate 0.01mg/kg via intravascular catheter. Removing endotracheal tube when sevofulrane at MAC 0.4, spontaneously generating tidal volume of \>4ml/kg, EtCO2\<45mmHg, Train of four ratio \>70-90%.
The invention discloses a salvianolic acid A magnesium salt, specially, relates to the salvianolic acid A magnesium salt, a preparation method and a use of the salvianolic acid A magnesium salt, and a salvianolic acid A magnesium salt-containing freeze-dried powder injection composition, and belongs to the technical field of medicines. The preparation method of the salvianolic acid A magnesium salt comprises the following steps of adding magnesium hydroxide into water, feeding CO2 into the magnesium hydroxide solution until the magnesium hydroxide solution is clarified, removing the CO2 in the magnesium hydroxide solution by ultrasonic waves to obtain magnesium hydrogen carbonate, adding salvianolic acid A into the obtained magnesium hydrogen carbonate so that the salvianolic acid A and the obtained magnesium hydrogen undergo a reaction at a temperature of 20 to 40 DEG C for 20 to 40 minutes to produce a reaction product solution, adding ethyl acetate into the reaction product solution, wherein the volume of the added ethyl acetate is equal to that of the reaction product solution, carrying out vortexing, and then carrying out centrifugal separation and freeze drying to obtain the salvianolic acid A magnesium salt. The salvianolic acid A magnesium salt has strong stability in an aqueous solution, high solubility and small irritation. The preparation method of the salvianolic acid A magnesium salt adopts a good preparation technology and has the simple steps. The salvianolic acid A magnesium salt-containing freeze-dried powder injection composition has good stability and high uniformity, and satisfies medicine rehydration capability requirements. The salvianolic acid A magnesium salt can be utilized for preparation of medicines for treating ischemic stroke.
A system supports creation and modification of a flexible and comprehensive organization structure model able to support provision of clinical care, patient tracking, billing and administration via a user friendly display interface. A method maintains organization related information for use in supporting organization operation. The method involves establishing a profile comprising information identifying an encompassing organization structure including information identifying a plurality of constituent organizations. The profile incorporates attributes for constituent individual organizations including, a constituent organization type identifier, and a user determinable role identifier. The role identifier indicates a role of a constituent organization in the encompassing organization structure. The method also involves employing the profile in providing a user with information concerning a constituent organization in response to user command.
Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its tissues and organs. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an enzyme released in response to the drop in cholesterol level occurring in sepsis. Our study aimed to evaluate the prognostic role of serum Proprotein convertase subtilisin/kexin type 9 (PCSK9) level in children with sepsis and severe sepsis. Sixty children were included in this study. They were divided into two groups: 30 children in the sepsis group and 30 in the severe sepsis group. Another 30 apparently healthy children were included as a control group. Blood samples were withdrawn from all included children for complete blood count (CBC), renal function tests (RFT), liver function tests (LFT), LDL-cholesterol (LDL-C), blood culture, and serum PCSK9. In this study, PCSK9 and LDL-C were higher in the two sepsis groups than in the control group (p < 0.05). They were also higher in the severe sepsis group than the sepsis group and in the non-survivors than in the survivors (p < 0.05). PCSK9 was positively correlated with length of hospital stay in surviving children (r = 0.67, p = 0.001) and had predicted significant hematological dysfunction (adjusted B =  - 96.95, p = 0.03). In conclusion, the PCSK9 assay can be used as a biomarker for bad prognosis in children suffering from clinical sepsis.
Participants will be treated with cognitive therapy by a psychologist. Administration of tinnitus intensity on a scale of 0-10 and questionary.
TVI-Brain-1 immunotherapy is integrated with radiation and temozolomide in the test group in the following manner: 1) Subjects undergo surgical resection of their cancer and are tapered off steroids. 2) Subjects receive the first vaccination of TVI-Brain-1 as soon as the laboratory prepared vaccine is available for use (approximately 7 - 14 days following surgery). 3) Subjects receive a second vaccination 7-10 days later. 4) Subjects are leukapheresed to obtain immune T cells for ex vivo-activation. 5) Subjects' T cells are stored frozen until after chemoradiotherapy is completed. 6) Following chemoradiotherapy Subjects are infused with activated effector T cells followed by a 10-day course of low-dose interleukin 2 (IL-2). 7) Subjects then proceed with post therapy surveillance.
Heart failure with preserved ejection fraction (HFpEF) is prevalent, increasing in incidence and has a poor prognosis. Accurate left ventricular (LV) haemodynamic assessment is needed to diagnose and manage patients with HFpEF. The reference method for assessment is an invasive study using catheters to measure intra-ventricular pressure but this is rarely done due to its invasive nature, high procedural costs and lack of expertise, despite the fact that haemodynamic guided therapy is associated with reduced re-hospitalisation and mortality. Non-invasive methods of LV haemodynamic assessment are inaccurate. The Investigators have developed an accurate four-dimensional flow cardiac magnetic resonance (4D flow CMR) protocol which is non-invasive and addresses the issues with existing practices to evaluate HFpEF. This observational-analytical study aims to assess the utility of a non-invasive 4D flow CMR protocol for haemodynamic assessment of HFpEF, to generate clinical data to support future clinical trials, clinical translation and patient benefit. This research study will involve generating a precise haemodynamic model using invasive and non-invasive data of prospectively recruited patients. This model will be also optimised in clinical patients with arrhythmias. Also, observational data will be collected to test the model's prognostic value.
<P>PROBLEM TO BE SOLVED: To provide a multilayer liposome which is readily prepared and is stable with time and a multilayer liposome preparation.  <P>SOLUTION: The multilayer liposome comprises (A) a polar lipid, (B) a nonionic surfactant having 1-9 HLB, (C) a nonionic surfactant having >9 and ≤20 HLB and water in a weight ratio [(C)/(A) + (B)] of 0.8-3.5. The multilayer liposome preparation is obtained by formulating the multilayer liposome with (E) a physiologically active substance. The multilayer liposome which is readily prepared and is stable with time and has a high concentration can simply and stability be mass-produced. The multilayer liposome can be used for applications e.g. cosmetics, external preparations such as medicines, fertilizers and agrochemicals as a highly functional material, because a water-soluble, an oil-soluble or an amphipathic physiologically active substance can be encapsulated in the multilayer liposome.  <P>COPYRIGHT: (C)2004,JPO
Polybrominated diphenyl ethers (PBDEs) have been detected in various environmental media and human tissues. PBDEs concentrations in dust from college buildings and homes and in paired hair and urine samples from students were determined. This is of great significance to explore the accumulation and excretion patterns of PBDEs in the human body. The median PBDEs concentrations in the dust (College: 84.59 ng/g; Home: 170.32 ng/g) and hair (undergraduate: 6.16 ng/g; Home: 3.25 ng/g) samples were generally lower than were found in the majority of previous studies. The PBDEs concentrations in the hair and urine samples were subjected to principal component analysis, and the results combined with the PBDEs detection rates confirmed that hair is a useful non-invasive sampling medium for assessing PBDEs exposure and the risks posed. Body mass indices (BMIs) were used to divide students who had not been exposed to large amounts of PBDEs into groups. Body fat percentage is an important factor affecting the accumulation of PBDE in the human body. Environmental factors were found to affect the PBDEs concentrations in the hair and urine samples less for normal-weight students (BMI≤24) than overweight students (BMI>24). Short-term environmental changes to more readily affect the PBDEs concentrations in the tissues of the normal-weight than overweight students. PBDEs with seven or more bromine substituents were found not to be readily excreted in urine. Performing molecular docking simulations of the binding of isomers BDE-99 and BDE-100 to megalin. The binding energy was higher for BDE-100 and megalin than for BDE-99 and megalin, meaning BDE-99 would be more readily excreted than BDE-100.
PURPOSE: Research on interocular synchronicity in amblyopia has demonstrated a deficit in synchronization (i.e., a neural processing delay) between the two eyes. Current methods for assessing interocular delay are either costly or ineffective for assessments in severe amblyopia. In this study, we adapted a novel protocol developed by Burge and Cormack based on continuous target tracking to measure the interocular delay on a wide range of amblyopes. Our main aims were to assess the accessibility of this protocol and to investigate the relationship between interocular delay and visual acuity.
METHODS: This protocol, which consists of tracking a target undergoing random lateral motion with the mouse cursor, is performed both binocularly and monocularly. The processing speed of a given eye is computed by comparing the changes in velocity of the target and mouse via cross-correlation. The difference in processing speed between the eyes defines the interocular delay.
RESULTS: Cross-correlations revealed that the amblyopic eye tends to be delayed in time compared with the fellow eye. Interocular delays fell in the range of 0.6 to 114.0 ms. The magnitude of the delay was positively correlated with differences in interocular visual acuity (R2 = 0.484; P = 0.0002).
CONCLUSIONS: These results demonstrate the accessibility of this new protocol and further support the link between interocular synchronicity and amblyopia. Furthermore, we determine that the interocular delay in amblyopia is best explained by a deficit in the temporal integration of the amblyopic eye.
The nasty urine microenvironment (UME) impedes neourethral regeneration by inhibiting angiogenesis and inducing an excessive inflammatory response. Cellular adaptation to hypoxia improves regeneration in numerous tissues. In this study, heterogeneous porous hypoxia-mimicking scaffolds were fabricated for urethral reconstruction via promoting angiogenesis and modulating the inflammatory response based on sustained release of dimethyloxalylglycine (DMOG) to promote HIF-1α stabilization. Such scaffolds exhibit a two-layered structure: a dense layer composed of electrospun poly (l-lactic acid) (PLLA) nanofibrous mats and a loose layer composed of a porous gelatin matrix incorporated with DMOG-loaded mesoporous silica nanoparticles (DMSNs) and coated with poly(glycerol sebacate) (PGS). The modification of PGS could significantly increase rupture elongation, making the composite scaffolds more suitable for urethral tissue regeneration. Additionally, sustained release of DMOG from the scaffold facilitates proliferation, migration, tube formation, and angiogenetic gene expression in human umbilical vein endothelial cells (HUVECs), as well as stimulates M2 macrophage polarization and its regulation of HUVECs migration and smooth muscle cell (SMCs) contractile phenotype. These effects were downstream of the stabilization of HIF-1α in HUVECs and macrophages under hypoxia-mimicking conditions. Furthermore, the scaffold achieved better urethral reconstruction in a rabbit urethral stricture model, including an unobstructed urethra with a larger urethral diameter, increased regeneration of urothelial cells, SMCs, and neovascularization. Our results indicate that heterogeneous porous hypoxia-mimicking scaffolds could promote urethral reconstruction via facilitating angiogenesis and modulating inflammatory response.
Individually titrate TARGINIQ ER to a dose that provides adequate analgesia and minimizes adverse reactions. Continually reevaluate patients receiving TARGINIQ ER to assess the maintenance of pain control and the relative incidence of adverse reactions, as well as monitoring for the development of addiction, abuse, and misuse [see Warnings and Precautions (5.1)]. Frequent communication is important among the prescriber, other members of the healthcare team, the patient, and the caregiver/family during periods of changing analgesic requirements, including initial titration. During chronic therapy, periodically reassess the continued need for the use of opioid analgesics.

Patients who experience breakthrough pain may require a dosage adjustment of TARGINIQ ER or may need rescue medication with an appropriate dose of an immediate-release analgesic. If the level of pain increases after dose stabilization, attempt to identify the source of increased pain before increasing the TARGINIQ ER dose.

As a guideline, the dose of TARGINIQ ER can be up-titrated from the current dose by increasing the dose 10 mg/5 mg q12h every 1 to 2 days as needed based on efficacy, safety, and tolerability. The total daily dose of TARGINIQ ER should not exceed 80 mg/40 mg (40 mg/20 mg q12h).

The highest total daily dose of TARGINIQ ER studied in the main clinical program is 80 mg/40 mg (40 mg/20 mg twice daily). Total daily doses above 80 mg/40 mg have not been studied sufficiently to ensure patient safety and may be associated with symptoms of opioid withdrawal or decreased analgesia.

If unacceptable opioid-related adverse reactions are observed, consider reducing the dosage. Adjust the dosage to obtain an appropriate balance between management of pain and opioid-related adverse reactions.

There are no well-controlled clinical studies evaluating the safety and efficacy with dosing more frequently than every 12 hours.
1. An aerosol composition which comprises an amino type drug bearing a functional group sensitive to oxidative and/or hydrolytic reaction in a solution of a liquefied HFA propellant, a co-solvent selected from pharmaceutically acceptable alcohols, wherein the pH of the solution has been adjusted to between 2.5 and 5.0 by addition of small amounts of a mineral acid such as hydrochloric, nitric or phosphoric acid. 2. A composition according to claim 1, wherein the pH of the solution has been adjusted between 3.0 and 3.5. 3. A composition according to claims 1-2, wherein the solution includes a low volatility component with a vapour pressure at 25 degree C not more than 0.1 kPa, preferably not more than 0.05 kPa. 4. A composition according to any preceding claim, wherein the solution includes at least 0.2% by weight of the low volatility component and not more than 10% by weight. 5. A composition according to claims 1-4, wherein the cosolvent is an alcohol, preferably ethanol. 6. A composition according to claims 3-5, wherein the low volatility component is selected from a glycol or an ester. 7. A composition according to claim 6, wherein the low volatility component is isopropyl myristate. 8. A composition according to any preceding claim, wherein the propellant includes one or more HFAs selected from the group comprising HFA 134a and HFA 227. 9. A composition according to any preceding claim wherein the active ingredient is ass2-agonist selected from salbutamol, formoterol, salmeterol and TA-2005, salts thereof or their combination with steroid such as beclomethasone dipropionate, fluticasone propionate, budesonide and its 22R-epimer. 10. A pressurised metered dose inhaler for aerosol administration consisting of a container having part or all of its internal metallic surfaces made of stainless steel, anodised aluminium or lined with an inert organic coating, containing a composition according to claims 1-9. 11. A method of filling the inhaler of claim 10, the method comprising: (a) preparation of a solution of one or more active ingredients in one or more co-solvents optionally containing an appropriate amount of a low volatility component; (b) filling the device with said solution; (c) adding a pre-determined amount of a strong mineral acid; (d) adding a propellant containing a hydrofluoroalkane (HFA); (e) crimping with valves and gassing.
Participants randomized to this group will receive the combination therapy of non-selective beta-blocker (NSBB) and endoscopic band ligation (EBL) . NSBB, including propranolol and carvidilol, will be started at day 5 after the index bleeding and elective EBL sessions started 2 weeks after the index bleeding.
1,157,022. Purification of tetracycline-antibiotics. CHAS. PFIZER & CO. Inc. 24 Nov., 1966 [3 Aug., 1966], No. 52730/66. Heading C2A. An improvement in the process for obtaining a complex of a tetracycline antibiotic from an aqueous medium containing a fermentationproduced tetracycline antibiotic obtained from a filtered and decalcified fermentation broth, by reacting at least a molar equivalent amount of a quaternary ammonium salt therewith at a pH of from 5 to 12, is characterized in that the quaternary ammonium salt has the formula: wherein R is alkyl having 9 to 18 carbon atoms and X is chloride, bromide or iodide. The preferred pH range is 8 to 11 and the antibiotic quaternary ammonium complex is separated as a precipitate or extracted with a waterimmiscible polar organic solvent. The antibiotic as free base or salt is recovered from the organic solvent solution by conventional methods. Typical quaternary ammonium salts are trimethyl 2-methyl decylammonium chloride, trimethyl 2-methylhexadecylammonium chloride and especially Arquad L-11 (mainly C 10-13  alkyl) and Arquad L-15 (mainly C 14  to C 19  alkyl) trimethyl 2-methyl alkyl ammonium chlorides. The tetracycline-antibiotic may be tetracycline, oxytetracycline, chlortetracycline or 7-chloro-6-demethyl tetracycline. Specification 775,916 is referred to.
Sleep disorders are common in people with Parkinson's disease. These disorders, which increase in frequency throughout the course of the neurodegenerative disease and impair quality of life, include insomnia, excessive daytime sleepiness, circadian disorders, obstructive sleep apnoea, restless legs syndrome, and rapid eye movement (REM) sleep behaviour disorder. The causes of these sleep disorders are complex and multifactorial, including the degeneration of the neural structures that modulate sleep, the detrimental effect of some medications on sleep, the parkinsonian symptoms that interfere with mobility and comfort in bed, and comorbidities that disrupt sleep quality and quantity. The clinical evaluation of sleep disorders include both subjective (eg, questionnaires or diaries) and objective (eg, actigraphy or video polysomnography) assessments. The management of patients with Parkinson's disease and a sleep disorder is challenging and should be individualised. Treatment can include education aiming at changes in behaviour (ie, sleep hygiene), cognitive behavioural therapy, continuous dopaminergic stimulation at night, and specific medications. REM sleep behaviour disorder can occur several years before the onset of parkinsonism, suggesting that the implementation of trials of neuroprotective therapies should focus on people with this sleep disorder.
The invention provides a novel nano antibody, a medicament, a preparation method and an application aiming at IL-17A, belonging to the technical field of cell immunology. The antibody comprises 3 complementarity determining regions HCDR1, HCDR2 and HCDR3, wherein the amino acid sequence of the HCDR1 is shown as SEQ ID NO. 1, the amino acid sequence of the HCDR2 is shown as SEQ ID NO. 2, and the amino acid sequence of the HCDR3 is shown as SEQ ID NO. 3; and/or; amino acid sequences having at least 80% sequence similarity with SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3, respectively. Compared with a positive antibody Ixekizumab, the antibody has higher affinity, better binding activity with Human IL-17A protein, good blocking effect and strong stability.
Ataxias are characterized by aberrant movement patterns closely related to cerebellar dysfunction. Purkinje cell axons are the sole outputs from the cerebellar cortex, and dysfunctional activity of Purkinje cells has been associated with ataxic movements. However, the synaptic characteristics of Purkinje cells in cases of ataxia are not yet well understood. The nicotinamide antagonist 3-acethylpyridine (3-AP) selectively destroys inferior olivary nucleus neurons so it is widely used to induce cerebellar ataxia. Five days after 3-AP treatment (65mg/kg) in adult male Sprague-Dawley rats, motor incoordination was revealed through BBB and Rotarod testing. In addition, in Purkinje cells from lobules V-VII of the cerebellar vermis studied by the Golgi method, the density of dendritic spines decreased, especially the thin and mushroom types. Western blot analysis showed a decrease in AMPA and PSD-95 content with an increase of the α-catenin protein, while GAD-67 and synaptophysin were unchanged. Findings suggest a limited capacity of Purkinje cells to acquire and consolidate afferent excitatory inputs and an aberrant, rigid profile in the movement-related output patterns of Purkinje neurons that likely contributes to the motor-related impairments characteristic of cerebellar ataxias.